Who is closest to a real anti-aging drug today?
In our longevity market deck, you will find everything you need to understand the market
SUMMARY
Life Biosciences is closest to a real human anti-aging drug today because ER-100 is the first publicly disclosed direct partial-reprogramming therapy to reach human dosing.
The race is becoming real because several programs are now in formal trials, not because anyone has proved that human aging can be slowed. Human exposure has begun across reprogramming, inflammation, nutrient sensing, autophagy and animal longevity.
Clinical stage alone gives a distorted picture. A conventional pill aimed at obesity or cardiovascular risk can move through familiar trials faster than a gene therapy that tries to reset an old cell, even when the gene therapy addresses aging more directly.
ER-100’s lead is important but narrow. The first trial involves a small number of patients, local delivery to the eye and a safety-first design; success would establish tissue-level rejuvenation, not whole-body age reversal.
Loyal is further ahead with regulators than any human longevity company, but it is developing a drug for dogs. Its STAY study could still become the field’s first large controlled test of lifespan and healthspan in a mammal living in ordinary homes.
BioAge and Cambrian may have more practical routes to normal prescriptions. Their oral drugs fit established development pathways, although their current endpoints mainly test inflammation, metabolism and cardiovascular risk rather than aging across several systems.
Rapamycin still has the strongest repeated lifespan evidence in mice, yet it has never received the large human outcomes trial needed to show fewer diseases, less disability or longer healthy survival. Metformin has lost ground for the opposite reason: its defining trial remains unfinished while newer programs have moved into the clinic.
GLP-1 drugs already deliver genuine healthspan gains for high-risk patients by preventing major cardiovascular events and improving function. That makes them more useful today than most supposed anti-aging products, but it does not prove that they slow aging in otherwise healthy people.
Senolytics have had the roughest first encounter with human trials. Unity’s failures and the limited scope of newer skin results suggest that senescent cells will need to be targeted by tissue and disease, not treated as one uniform enemy.
The ranking could change quickly. A durable improvement in human vision after ER-100, healthier survival in Loyal’s dog trial, or a large human outcomes win for an mTOR drug would outweigh another funding round, biomarker shift or animal study.
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
Why is the anti-aging drug race becoming real now?
The anti-aging drug race has become a real clinical race because several serious programs are now dosing people or running formal longevity trials.
For decades, longevity science produced impressive worms, flies and mice while human evidence stayed thin. That gap has started to close. Life Biosciences dosed the first participant in its ER-100 Phase 1 study in June 2026. BioAge began dosing people in QUELL-CV, a Phase 2 trial of its oral NLRP3 inhibitor BGE-102. Retro Biosciences says its autophagy drug RTR242 moved from indication selection to first-in-human dosing in 15 months. Cambrian has reported Phase 1b human data for ATX-304 and now lists the program as entering Phase 2.
Loyal has advanced even further on the regulatory side. The company says LOY-002 has completed two of the three major technical requirements for FDA conditional approval. Its 1,300-dog STAY study is also fully enrolled across 70 veterinary practices.
These programs belong to four different categories: cellular reprogramming, inflammation control, nutrient-sensing drugs and animal longevity. Together, they show that serious testing has begun. Proof that aging itself is treatable is still missing.
What should count as a real anti-aging drug?
A real anti-aging drug should change an aging process and produce a meaningful human benefit, preferably across more than one disease or organ system.
That standard rules out two easy shortcuts. A medicine does not qualify simply because older people use it. Statins, cancer treatments and osteoporosis drugs can save lives without slowing the wider aging process. A treatment also needs more than a younger-looking biomarker. An epigenetic clock, inflammatory marker or metabolic measure becomes convincing only when it connects to better function, fewer diseases or longer healthy survival.
We would accept three levels of evidence. The first is convincing rejuvenation of one human tissue, provided the treatment repairs age-related damage through a mechanism that could work elsewhere. The second is delayed onset of several age-related conditions. The strongest level is longer healthy lifespan in a controlled human study.
The comparison gets tricky here. Conventional pills can move through familiar disease trials quickly, but their results often say little about aging as a whole. Reprogramming therapies attack the biology more directly and carry much higher risks around delivery, immune reactions and abnormal cell behavior. Clinical stage alone can therefore produce a bad ranking.
We also use “drug” broadly enough to include gene therapies and biological products. Restricting the word to pills would make the comparison tidier while excluding the field’s most direct attempt at rejuvenation.
| Evidence level | What would qualify | How close are we? |
|---|---|---|
| Tissue rejuvenation | Restored function in an aged human tissue through an aging mechanism | ER-100 is testing this now |
| Multi-disease healthspan | Delayed cardiovascular disease, cancer, dementia or disability in one trial | No program has shown it |
| Longer healthy life | More years alive with preserved function | Being tested in dogs, not humans |
| Biomarker change alone | Lower inflammation or a younger biological-age score | Useful evidence, but insufficient |
If you want more recent data on this point, please see our latest longevity market report.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Who leads the anti-aging drug race today?
We rank Life Biosciences first today because ER-100 attacks cellular aging more directly than the other clinical contenders.
ER-100 is the first publicly disclosed direct reprogramming therapy to enter a human trial. It uses an AAV-delivered combination of OCT4, SOX2 and KLF4, usually called OSK, to reset part of the cell’s epigenetic program while preserving its identity.
Other companies lead different parts of the race. BioAge has one of the most advanced standard oral programs. Cambrian has reported early human metabolic effects. Retro has brought an autophagy drug into the clinic for Alzheimer’s disease. Loyal is furthest along with the FDA, but its patients are dogs.
Rapamycin needs its own category. It is already approved for other medical uses and has repeatedly extended lifespan in mice. Human studies remain too small and inconsistent to show broad anti-aging effects.
| Current position | Contender | Strongest evidence now | Main limitation |
|---|---|---|---|
| Direct human rejuvenation leader | Life Biosciences | ER-100 is dosing people in Phase 1 | Small, local eye study |
| Regulatory longevity leader | Loyal | Two major conditional-approval requirements completed | Dog drug |
| Conventional clinical leader | BioAge | BGE-102 dosing in Phase 2 | Biomarker-led cardiovascular program |
| Metabolic geroscience contender | Cambrian | Positive Phase 1b data; ATX-304 entering Phase 2 | Obesity and cardiometabolic endpoints |
| Early human platform contender | Retro Biosciences | RTR242 reached first-in-human dosing | Alzheimer’s program, not reprogramming |
| Best-known existing molecule | Rapamycin | Strong repeated mouse evidence; limited human trials | No decisive human healthspan trial |
Is Life Biosciences really trying to reverse human aging?
Yes. ER-100 directly targets cellular rejuvenation, starting with damaged optic nerves.
ER-100 delivers OSK factors to retinal ganglion cells, the neurons that carry visual information from the eye to the brain. Aging, glaucoma and ischemic injury can leave these cells damaged and poor at regeneration. The therapy is designed to restore a younger pattern of gene activity and help them recover function.
Partial reprogramming grew out of experiments showing that mature cells can be pushed back toward a younger state. Full reprogramming goes much further and can erase cellular identity, which would be dangerous inside an organ. The partial approach tries to stop earlier, after repairing some age-related changes but before a retinal neuron forgets that it is a retinal neuron.
That mechanism puts ER-100 in a different category from anti-inflammatory or metabolic drugs. BioAge is suppressing NLRP3-driven inflammation. Cambrian is activating the AMPK network. Rapamycin changes nutrient-sensing and growth pathways. All are relevant to aging, while ER-100 attempts to rewrite the state of the old cell itself.
The standard for success is straightforward. A younger molecular profile would be interesting. Restored sight would be far more convincing. Until human function improves, “rejuvenation” describes the intended mechanism, not an established clinical result.
This chart, featured in our longevity market deck, illustrates yearly VC funding for longevity startups
How strong is the evidence behind ER-100?
ER-100 has some of the strongest animal evidence in rejuvenation research, but human benefit remains completely unproven.
The key mouse work appeared in Nature. Researchers expressed OSK in retinal ganglion cells after optic-nerve injury and in models of glaucoma and age-related vision loss. They reported three linked effects: younger molecular patterns, renewed axon growth and improved visual function. That combination is more convincing than a clock moving on its own because the same tissue showed molecular, structural and functional change.
The experiments also included older animals and treatment after damage had occurred. Repairing an already aged nervous system is a much harder test than preventing damage in young mice. The work suggested that cells retain some form of youthful information that can be recovered.
Life Biosciences later reported nonhuman-primate data showing delivery to retinal ganglion cells and preservation of visual and structural measurements after ischemic optic injury. Those results narrow the gap between mice and people. We give them less weight than the original mouse study because the detailed primate evidence remains less independently developed in public.
The animal evidence easily justifies a cautious Phase 1 trial. It does not justify claims about human age reversal.
If you want more recent data on this point, please see our latest longevity market report.
What can the first ER-100 human trial actually prove?
The first ER-100 trial can show whether human cells tolerate partial reprogramming and whether damaged vision begins to recover.
According to the current ClinicalTrials.gov record, the Phase 1 study plans to enroll 18 adults with open-angle glaucoma or non-arteritic anterior ischemic optic neuropathy. Participants receive a single dose and undergo detailed eye examinations, laboratory testing and long-term follow-up for up to five years. Safety and tolerability are the main goals, with visual function included among the additional measures.
A clean safety result would be a major achievement. Researchers need to show that OSK expression can be switched on at a useful level without provoking serious inflammation, damaging the retina, changing cell identity or encouraging abnormal growth. Gene therapies also require long follow-up because some problems can emerge slowly.
The most valuable early efficacy result would combine better vision with objective evidence from retinal structure or nerve activity. Improvement on a questionnaire alone would carry little weight. A consistent change across visual fields, imaging and electrophysiology would make the animal findings much harder to dismiss.
The eye gives Life Biosciences a practical advantage. Treatment can be delivered locally, the tissue can be imaged repeatedly and function is measurable. It is also a very forgiving place to start compared with systemic treatment. Success in 18 patients would still be a local proof; heart muscle, immune cells and brain tissue may need different doses, delivery systems or reprogramming factors.
A positive trial would establish the first real human tissue-rejuvenation result. Whole-body anti-aging would remain several large steps away.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Is Loyal closer than every human anti-aging company?
Loyal is closest to an approved longevity product; Life Biosciences is closest to proving direct rejuvenation in humans.
LOY-002 is being developed for older dogs, and the FDA pathway is unusually advanced for a drug explicitly connected to lifespan. Loyal says the program has completed two of three major technical requirements for conditional approval. Its fully enrolled STAY study follows more than 1,300 older dogs through 70 veterinary practices in a randomized, double-blind, placebo-controlled design.
Dogs make longevity trials practical. Their shorter lives allow survival and health outcomes to appear within a few years. Companion dogs also develop cancer, metabolic disease, cognitive decline and mobility problems in normal homes rather than laboratory cages.
STAY’s biggest advantage is what it measures. Loyal is collecting lifespan, health and quality-of-life data instead of relying on one laboratory marker. A convincing result would give geroscience its first large, real-world longevity trial in a mammal that shares much of our environment.
The jump from dogs to humans could still fail. Dogs differ in metabolism, disease patterns and lifespan, and the company has disclosed limited detail about the molecule itself. Conditional approval also follows a different legal pathway from ordinary human drug approval.
Loyal could become the first company to sell a regulator-reviewed longevity medicine. That would reshape the field without answering whether the same idea works in people.
Is rapamycin already the best anti-aging drug available?
Rapamycin is the strongest existing geroscience candidate, but calling it a proven anti-aging drug goes beyond the human evidence.
Its animal record is unusually deep. Rapamycin has extended lifespan in genetically diverse male and female mice, at several doses and even when treatment started late in life. The drug inhibits mTOR, a pathway that links nutrients to growth, protein production and autophagy. The result has been repeated often enough that the mouse effect is difficult to dismiss.
Human studies are smaller and much less convincing. In the PEARL trial, 114 adults completed 48 weeks of weekly placebo or compounded rapamycin at two doses. The primary endpoint, visceral fat, did not improve. Some secondary findings involving lean tissue and pain looked encouraging, especially in women, but the subgroups were small.
Earlier trials of mTOR inhibitors found improvements in antiviral responses among older adults. A later program involving RTB101 produced an encouraging Phase 2b infection result under one analysis and then failed to show a consistent clinical benefit in Phase 3. That history is a useful warning: aging pathways can look powerful in early studies and disappoint when trials become larger or endpoints become stricter.
Commercial incentives also work against a definitive rapamycin trial. The molecule is generic, so no sponsor owns a long monopoly that would easily repay a large, multi-year prevention study. Newer companies are developing selective mTORC1 drugs that may offer cleaner safety and stronger patent protection.
We need a serious rapamycin outcomes trial. Until one is completed, self-experimentation and mouse survival cannot substitute for proof that healthy humans avoid disability or disease.
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Did metformin lose the anti-aging race?
Metformin has fallen behind because the trial meant to prove its anti-aging value still has no results, while newer programs are already dosing people.
The proposed TAME study remains important. Its design would test whether metformin delays a combined set of age-related outcomes rather than treating aging as a vague label. Roughly 3,000 older adults were expected to be followed for several years, creating a possible template for future geroscience trials.
TAME still has no results. Public materials from the American Federation for Aging Research continue to describe it as a future proof-of-concept study. During the long wait, the field’s center of gravity moved toward programs with active trials.
Metformin’s existing record is useful but ordinary. In the Diabetes Prevention Program, it reduced progression to diabetes by 31% over the original trial period, compared with 58% for intensive lifestyle intervention. That is meaningful prevention for people with prediabetes, but it does not show that healthy adults age more slowly.
The MET-PREVENT trial, published in The Lancet Healthy Longevity, delivered a more direct setback. In older adults with probable sarcopenia and prefrailty or frailty, metformin failed to improve physical performance, daily functioning or quality of life. Gastrointestinal side effects were common. One negative trial in a vulnerable population cannot settle every longevity hypothesis, but it weakens the idea that metformin is quietly producing broad functional rejuvenation.
Metformin remains cheap, familiar and worth studying. It no longer deserves first place based mainly on observational data and the promise of a trial that has taken years to materialize.
Are GLP-1 drugs already anti-aging medicines?
GLP-1 drugs are powerful healthspan medicines for high-risk patients, although they have not shown that normal human aging slows.
Semaglutide already has the kind of human evidence longevity startups can only envy. In the SELECT trial published by The New England Journal of Medicine, more than 17,000 adults with overweight or obesity and established cardiovascular disease, but without diabetes, received semaglutide or placebo. The drug cut major cardiovascular events by about 20% relative to placebo.
Other trials have shown better symptoms, physical limitations and exercise capacity in people with obesity-related heart failure. Those outcomes matter more to patients than a small shift in biological age. Preventing a heart attack and helping someone walk farther are concrete gains in healthy life.
The anti-aging label still stretches too far. SELECT enrolled people with obesity and existing cardiovascular disease. Semaglutide improves weight, appetite and metabolic risk in a population where those factors cause substantial harm. We do not know whether a metabolically healthy person would gain broader protection across unrelated tissues.
GLP-1 drugs may show how the first anti-aging era actually develops: several drug classes, each removing a major cause of late-life disability. That would extend healthspan without proving that the underlying rate of aging has changed.
| Question | GLP-1 evidence today | Verdict |
|---|---|---|
| Do the drugs improve major human outcomes? | Yes, including fewer cardiovascular events in selected high-risk patients | Strong |
| Do they improve function? | Yes, in obesity-related heart failure studies | Strong |
| Do they slow aging across healthy people? | No convincing trial yet | Unproven |
| Are they more useful today than speculative supplements? | Clearly | Yes |
| Are they general anti-aging drugs? | The evidence does not reach that far | No |
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Have senolytics survived their first human reality check?
The first wave of senolytics has failed to produce a convincing human win.
Senescent cells stop dividing and release inflammatory molecules that can damage nearby tissue. Removing selected senescent cells improved several diseases and aspects of function in mice, creating hope that one drug class could treat many consequences of aging.
Unity Biotechnology supplied the hardest test. UBX0101 failed to reduce pain in a Phase 2 knee-osteoarthritis study, and the company discontinued the program. Its next drug, UBX1325, produced comparable visual gains to aflibercept at several points in a Phase 2b eye study but missed the trial’s prespecified primary non-inferiority endpoint.
Unity’s business history makes the pattern harder to ignore. After the eye results, Unity cut operations, explored strategic alternatives and later filed a plan for liquidation and dissolution. A company that once represented the commercial front line of senolytics never converted promising mouse biology into a clear clinical victory.
Rubedo Life Sciences has kept the category alive. In June 2026, it reported a 46% reduction in actinic keratosis lesions after four weeks in preliminary Phase 1b/2a results for RLS-1496. The finding is early, local and company-reported, so it cannot carry the wider anti-aging claim yet.
A recent Nature Aging review reached the same broad verdict: early trials have produced biological effects, but clear human efficacy remains missing. The likely problem is heterogeneity. A harmful senescent cell in arthritic cartilage may behave very differently from one in the retina or skin, and some senescent cells help with wound healing.
Senolytics may still work once researchers identify the right cell, tissue and treatment window. We currently place the category behind reprogramming, mTOR and conventional inflammation programs.
If you want more recent data on this point, please see our latest longevity market report.
Is BioAge the strongest conventional anti-aging biotech?
BioAge currently has the strongest conventional pill program built explicitly from human aging biology.
Its lead drug, BGE-102, blocks NLRP3, part of an inflammatory pathway linked to cardiovascular, metabolic and neurological disease. The molecule is oral and brain-penetrant, making it much easier to dose broadly than a local gene therapy.
In its completed Phase 1 readout, BioAge reported median reductions of at least 85% in high-sensitivity C-reactive protein at the 60-milligram and 120-milligram daily doses among participants with obesity and elevated inflammation. QUELL-CV is now underway in people with obesity and cardiovascular risk factors. The primary endpoint focuses on inflammatory biomarkers, including hsCRP.
The program looks like a normal pharmaceutical product: an oral drug, a familiar endpoint and a standard development path. If BGE-102 is safe and able to suppress inflammation consistently, BioAge will have a strong cardiovascular-development candidate. The anti-aging claim requires a longer chain of proof. Lower hsCRP must eventually translate into fewer heart attacks, strokes, functional losses or other meaningful outcomes.
BioAge’s history also gives us a reason to stay demanding. The company discontinued azelaprag after liver-enzyme elevations appeared in an obesity study. A target discovered through longevity data faces the same toxicity and execution risks as any other drug.
BioAge may reach a conventional prescription product before Life Biosciences. Life Biosciences stays ahead on direct rejuvenation because ER-100 tries to reset aged cells at a deeper level than one inflammatory pathway.
This chart, featured in our longevity market deck, illustrates how revenue is distributed across customer segments in the longevity market
Are Cambrian and Retro Biosciences taking a smarter route?
Cambrian and Retro have sensible routes to approval, but their human trials currently focus on specific diseases.
Cambrian’s ATX-304 activates the AMPK network, a central regulator of cellular energy. At the American Diabetes Association’s 2026 meeting, Cambrian reported Phase 1b changes in resting metabolism, liver fat, visceral fat, triglycerides and adiponectin among adults with obesity and prediabetes. These appeared at doses below those expected to cause major weight loss. Cambrian now lists ATX-304 at Phase 2, with REWIRE studies planned.
This route is practical. Metabolic endpoints can be measured within months, and regulators already understand obesity and cardiometabolic disease. Positive results would validate the drug while leaving the broader geroscience claim for later studies.
Retro has moved RTR242, an oral autophagy drug for Alzheimer’s disease, into first-in-human testing. Its more radical programs include cell replacement and AAV-delivered tissue reprogramming for osteoarthritis and age-related hearing loss, but those remain preclinical or in IND-enabling work.
The two companies are avoiding an all-or-nothing bet. That may produce a successful medicine sooner, but their most advanced human assets give us a less direct answer on whether old cells can be rejuvenated.
For investors or drug developers, this route may be smarter. For this ranking, one fact carries the most weight: ER-100 is already testing the central rejuvenation claim in people.
Why are Altos Labs, NewLimit and Calico not leading?
Altos Labs, NewLimit and Calico could become major winners, but their public human evidence still trails the leaders.
Altos has built a large research organization around cellular rejuvenation, resilience and disease reversal. It has recruited a chief medical officer and product-development leadership, showing a clearer move toward translation. The company still has no publicly identified clinical-stage rejuvenation therapy comparable with ER-100.
NewLimit is developing epigenetic-reprogramming medicines for metabolic, vascular and immune cells. Its discovery system combines single-cell genomics, high-throughput experiments and machine learning. A $435 million Series C in 2026 gave the company enormous room to move toward human trials. Its public programs remain preclinical.
Calico is clinically mature in a different sense. It has several disease programs, including a Phase 2 anti-PAPP-A antibody for polycystic kidney disease and a therapy for vanishing white matter disease that recently received FDA Breakthrough Therapy Designation. Those are serious drug-development achievements tied to age-related biology, but they do not demonstrate slowed aging or cellular rejuvenation across systems.
Money, talent and strong research increase the chance of future success. They cannot replace a disclosed candidate, human dosing and interpretable results. Any of these companies could overtake Life Biosciences quickly once a direct rejuvenation program enters the clinic.
This chart, featured in our longevity market deck, shows how longevity plan technology has evolved over time
What result would change the anti-aging ranking fastest?
A clear improvement in human function would change this ranking faster than another biomarker result.
Life Biosciences would strengthen its lead by showing better vision together with objective retinal or nerve measurements and an acceptable safety profile. Even a small effect would matter if it appeared consistently across several tests and lasted.
Loyal could transform the regulatory debate if STAY shows that treated dogs live longer and remain healthier. The field would gain a large controlled longevity result in a mammal living in ordinary homes, plus a practical model for combining lifespan and quality-of-life endpoints.
BioAge needs to connect NLRP3 suppression with clinical outcomes. A large hsCRP reduction shows target engagement; fewer cardiovascular events would show medical value. Cambrian could move up by demonstrating that ATX-304 preserves muscle, improves exercise capacity or produces durable metabolic benefits in Phase 2.
Rapamycin would regain the lead under a broad definition if a sufficiently large randomized trial showed fewer infections, cancers, cardiovascular events or functional losses without offsetting toxicity. NewLimit, Retro or Altos could leap near the top by entering humans with a systemic or multi-tissue reprogramming therapy.
| Contender | Result that would change the ranking | Why it would count |
|---|---|---|
| Life Biosciences | Safe, objective visual recovery after ER-100 | First functional human evidence for partial reprogramming |
| Loyal | Longer and healthier survival in STAY | First large mammalian longevity result built for FDA review |
| BioAge | Fewer cardiovascular events with BGE-102 | Moves beyond inflammation biomarkers |
| Cambrian | Preserved muscle or better physical function in Phase 2 | Connects metabolic biology to healthspan |
| Rapamycin or a selective mTORC1 drug | Fewer age-related diseases in a large trial | Links the strongest animal pathway to human outcomes |
| NewLimit, Retro or Altos | Human dosing of broader reprogramming therapy | Could surpass a local eye program |
Who is closest to a real anti-aging drug today?
We rank Life Biosciences closest to a real human anti-aging drug today, although the proof remains narrow and early.
Life Biosciences stays first because the alternatives fall into three weaker groups: dog longevity drugs, disease-specific pills and reprogramming platforms that remain preclinical. None matches ER-100’s combination of a direct aging mechanism and clinical progress.
Loyal leads the approval race because LOY-002 has advanced further through an FDA pathway, although it is a canine product. BioAge leads among standard oral drugs built from human aging biology. Cambrian is further along in metabolic geroscience. Rapamycin still owns the best-established animal record.
Even the leader remains far from a broad anti-aging medicine. ER-100 could succeed as an eye therapy and still fail to generalize to the heart, immune system or brain. Phase 1 may reveal safety without efficacy. A broad anti-aging medicine would eventually need durable benefits across several tissues or a clear reduction in multiple age-related diseases.
The current milestone is real but tightly bounded. Life Biosciences is closest to showing that one aged human tissue can be rejuvenated. Nobody is currently close to proving that a drug can slow aging across the whole human body.
If you want more recent data on this point, please see our latest longevity market report.
In our longevity market deck, we identify pain points entrepreneurs should prioritize
OUR METHODOLOGY
We treated this as a ranking of evidence, not a ranking of company size, funding or scientific reputation. The central test was whether a program directly targets an aging process, has entered a formal trial and can produce a meaningful functional or clinical result.
We separated tissue rejuvenation, multi-disease healthspan and longer healthy survival because they are different claims. A local improvement in an aged human tissue can establish a real rejuvenation result without proving that the same treatment slows aging across the body.
Clinical stage was used as one measure of execution, not as the final ranking rule. Conventional pills can move quickly through familiar obesity, cardiovascular or neurological trials, while direct reprogramming therapies face harder delivery and safety problems. We therefore gave more weight to the directness of the mechanism and the relevance of the endpoint.
We treated biomarkers as evidence of target engagement rather than proof of anti-aging benefit. Changes in hsCRP, metabolism or biological-age measures carried more weight when they were linked to function, disease reduction, tissue repair or survival.
Animal evidence mattered most when molecular, structural and functional changes appeared together and when treatment worked in older animals or after damage had occurred. Repeated mouse lifespan results supported rapamycin’s position, while nonhuman-primate delivery data helped assess whether ER-100’s eye program could plausibly translate beyond mice.
Regulatory progress was evaluated separately from human rejuvenation. Loyal leads the approval race because its canine program is advanced with the FDA, but we did not treat a dog-drug pathway as equivalent to proof in people.
We prioritized recent trial registrations, peer-reviewed studies, regulatory material and detailed company disclosures. Key sources included ClinicalTrials.gov for active human studies, Life Biosciences for ER-100 updates, Nature for the OSK retinal-reprogramming work, BioAge for BGE-102 and QUELL-CV, Cambrian for ATX-304, Retro Biosciences for RTR242, Loyal and the FDA’s animal-drug materials for LOY-002 and STAY, The New England Journal of Medicine for SELECT, The Lancet Healthy Longevity for MET-PREVENT, and Nature Aging for the state of human senolytic evidence.
The final ranking combines mechanism, clinical progress, endpoint quality, regulatory advancement and the amount of interpretation still required. A clear functional result in people would outweigh a larger funding round, a younger biomarker or another strong animal study.
This chart, featured in our longevity market deck, illustrates how revenue is distributed across Europe, Asia, North America, Africa, and South America in the longevity market
Related blog posts
- Has any longevity drug worked yet?
- Who is closest to reversing aging?
- Which startup looks most promising in reversing cellular aging?
